SEATTLE, WA October 12, 2018 — Cyrus Biotechnology, a Seattle-based firm offering access to Rosetta, the most advanced software available for protein modeling and accelerated drug discovery, announced today that it will present at the 10th Annual Immunogenicity & Bioassay Summit, to be held in Washington DC on October 22-25, 2018.
Dr. Indigo King, a computational protein design and immunology specialist, will present at the Immunogenicity Summit as follows:
Abstract: Computational protein design has the potential to create a novel class of therapeutics with tunable biophysical properties, but immunogenicity remains a concern. We have combined machine learning with structure-based protein design to identify and redesign T-cell epitopes without disrupting function of the target protein or creating new epitopes. We have verified the method experimentally, removing T-cell epitopes from a gene therapy target, an immunotoxin, and GFP while maintaining folding and function.
Date: Thursday, October 25th, 2018
Time: 3:25 PM EDT
Track: Immunogenicity Prediction & Control
Room: Edison ABC
Venue: The Westin Alexandria, 400 Courthouse Square, Alexandria, VA 22314
For more information on immunology with Cyrus, see Cyrus Biotechnology Launches Immune Epitope Prediction Software.
Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the Biopharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus was founded in 2014 as a spin-out from the University of Washington, and offers Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, engineering and design to accelerate discovery of Biologics and Small Molecules. Cyrus Bench is based primarily on the Rosetta software package from Prof. David Baker’s lab at the University of Washington, along with associated software. Cyrus Bench offers the world-leading protein structure prediction pipeline of Rosetta, as well as the only protein engineering software experimentally proven capable of designing entirely new proteins. Cyrus Bench is powered by Rosetta, which has been developed over near 20 years, and validated by well over 700 publications that demonstrate efficacy both in vitro and in vivo. Cyrus is financed by experienced investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Real Estate, the W Fund, and others.
NOTICE: The information contained in this document is dated as of October 12, 2018. Cyrus Biotechnology, Inc. (the Company) disclaims any obligation to update such information after such date. This document contains forward–looking statements reflecting the Company’s current expectations that necessarily involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in such forward-looking statements due to a number of factors and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
Cyrus Contact Lucas Nivon